UNSPSC 51192003: Probenecid

This classification denotes a uricosuric agent with the molecular formula C13H19NO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PO572Z7917, chemically known as 4-(n,n-dipropylsulfamoyl)benzoesaeure but generally known as probenecid, which bears US NIH Compound Identifier 4911. European Medicines Agency schedules Probenecid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10053MIG.

UNSPSC 51192003 Probenecid (Commodity) shows minimal alignment between the code's narrow pharmaceutical scope and recent state and local solicitations. Probenecid is a specific uricosuric agent used in gout and uric acid stone management; however, the three recent opportunities tagged under this code involve athletic training services, general medical aid supplies, and pharmacy benefit program strategy—none of which involve probenecid procurement or related pharmaceutical commodities. The City of Tucson's RFP for athletic training services to the Fire and Police Departments, posted May 13, 2026 with responses due June 9, 2026, solicits injury prevention, rehabilitation, and return-to-duty support delivered by certified athletic trainers under physician supervision. The City of Tampa Fire Rescue Department's ITB 25P00157 for medical aid supplies, posted April 24, 2026, covers a 32-item list including antiseptic sprays, hydrogen peroxide, aspirin, pain relievers, and bandages—general first-aid consumables rather than prescription pharmaceuticals. The Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, explores vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager channels; this is a strategic market-intelligence tool addressing prescription program design, not acquisition of a specific drug product.

Recent activity under this code does not reflect pharmaceutical procurement at the commodity level. The mismatch between probenecid's specific therapeutic use and the scope of posted opportunities suggests either systematic miscoding or that state and local agencies rarely solicit this pharmaceutical through standard UNSPSC taxonomy. Firms targeting state and local pharmaceutical spending should focus on higher-level UNSPSC families covering prescription drugs, medical supplies, or pharmacy services rather than this commodity code. No evidence of active procurement demand for probenecid itself appears in the recent record.